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Abstract
T lymphocytes are often induced naturally in melanoma patients and infiltrate tumors. Given that cd T cells mediate
antigen-specific killing of tumor cells, we studied the representation and the in vitro cytokine production and cytotoxic
activity of tumor infiltrating cd T cells from 74 patients with primary melanoma. We found that cd T cells represent the major
lymphocyte population infiltrating melanoma, and both Vd1+ and Vd2+ cells are involved. The majority of melanoma-
infiltrating cd cells showed effector memory and terminally-differentiated phenotypes and, accordingly, polyclonal cd T cell
lines obtained from tumor-infiltrating immune cells produced IFN-c and TNF-a and were capable of killing melanoma cell
lines in vitro. The cytotoxic capability of Vd2 cell lines was further improved by pre-treatment of tumor target cells with
zoledronate. Moreover, higher rate of cd T cells isolation and percentages of Vd2 cells correlate with early stage of
development of melanoma and absence of metastasis. Altogether, our results suggest that a natural immune response
mediated by cd T lymphocytes may contribute to the immunosurveillance of melanoma.
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Introduction
Melanoma is one of the more frequently studied cancers for the
evaluation of immunotherapy, and with its epidemic rise in
incidence across the world, it has become the focus of multiple
immunotherapy trials over the years. The evidences that
spontaneous regression of disease may occur in patients with
melanoma [1–3] and that increased numbers of tumor-infiltrating
lymphocytes (TILs) correlate to improved prognosis of melanoma
and other solid tumors [4,5] have argued for the importance of the
immune response in the clinical outcome of melanoma. In
addition, metastatic melanoma has a poor prognosis with a five-
year survival of less than 2% and very limited treatment options.
Approved treatments for metastatic melanoma include high-dose
interleukin-2 (IL-2) and chemotherapy [6,7], which have, at best,
an overall response rate of 16% and 7.5%, with very few complete
responders and almost no long-term survivors [7].
TILs are an immune population composed of different immune
cells that have specificity and potential reactivity against the
tumor. TILs have been found in a wide variety of solid tumors
including primary brain tumors, epithelial cancers, melanoma and
others [8–10]. Recent studies have reported high clinical response
rates in metastatic melanoma patients with TIL-based protocols in
combination with non-myeloablative lymphodepleting chemother-
apy (cyclophosphamide and fludarabine) immediately prior or
added to infusion of TIL and high-dose IL-2 therapy [11–13].
Other novel strategies include peptide vaccination and blocking
antibodies against the CTLA-4 [14–16] or the PD-1 molecule
[17–19]. Clearly, combination therapy with other agents or
perhaps modification of TILs has the potential to further improve
clinical responses, decrease the number of TILs needed for
therapy and/or decrease the toxicities associated with cyclophos-
phamide/fludarabine preparative regimens.
While the functions and anti-melanoma activities of CD4 and
CD8 T cells within TILs have been extensively studied [20–21],
very little is known about cd T lymphocytes. cd T lymphocytes are
important effector cells of the immune system that may play a role
in the anti-tumor surveillance in the periphery [22]. Human cd T
cells can be divided into two main populations based upon d chain
expression [23]: cd T cells expressing the Vd1 chain are most often
found in mucosal tissues, where they are involved in maintaining
epithelial tissue integrity in the face of damage, infection, or tumor
transformation, while cd T cells expressing the Vd2 chain
predominate in the peripheral blood and secondary lymphoid
organs [24]. While the ligand(s) recognized by Vd1+ cells remain
unknown, Vd2+ cells recognize non peptidic antigens by a MHC-
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unrestricted mechanism, an important feature which distinguishes
them from ab T cells [23]. Specifically, Vd2 T cells recognize
phosphoantigens that are produced through the isoprenoid
biosynthesis pathways [25–27]. Phosphoantigens are not stimula-
tory at physiologic levels, but transformed and infected cells,
produce increased levels of metabolic intermediates that are able
to activate Vd2 T cells [28–30]. Accordingly, Vd2 T cells can also
be activated, through an indirect mechanism, by aminobispho-
sphonates, a class of drugs used to treat certain bone diseases, that
inhibit farnesyl pyrophosphate synthase, and cause accumulation
of endogenous upstream metabolites such as isopentenylpyropho-
sphate (IPP) [31].
cd T cells may indirectly contribute to the immune defense
against cancer cells, by producing cytokines typical of Th1, Th2 or
Th17 cells [32–34], or cross-talking with dendritic cells [35],
macrophages [36] and B cells [37–38]. Additionally, cd T cells
perform cytotoxic activity toward cancer cells, which is mediated
in much the same manner as for ab T cells, through perforin/
granzyme, Fas/FasL, TNF/TNF-R and TRAIL-TRAIL-R path-
ways [24]. Moreover, the localization of cd T cells within epithelia
suggests that these cells may contribute to the surveillance of
malignancies, including melanoma [22]. Based on this, we
evaluated the representation and the in vitro cytokine production
and cytotoxic activity of tumor infiltrating cd T cells from 74
patients with primary melanoma. Moreover, we correlated levels
of infiltrating cd T cells and any of the established clinicopath-
ologic features described for melanoma.
Materials and Methods
Patients
We identified a consecutive series of patients who were treated
surgically at the Plastic Surgery Department of the University
Hospital in Palermo, from 2007 to 2010, for primary melanoma
and for whom fresh-frozen tissue and peripheral blood were
available for evaluation. A total of 74 patients (32 females and 42
males) were included and all were followed postoperatively for the
development of important clinical outcomes such as metastasis and
death. The median age at surgery was 60 years (range 26–80
years). Healthy subjects were volunteers in good and stable clinical
condition, and had laboratory parameters in the physiologic range.
Diagnosis of melanoma was histologically confirmed.
Melanoma morphology was superficial spreading (46%), nod-
ular (35%), acral lentiginous (5%), lentigo maligna (3%), spitzoid
(3%), and nevoid (1%).
All patients brought cutaneous primary melanoma and were
staged according to the new American Joint Committee on
Cancer staging system for cutaneous melanoma [39]. A blood
drawing was taken before the surgical excision. According to
Italian rules (art. 13, DLgs n. 196/03), this study did not require
authorisation by the local ethical committee. The study was
performed in accordance to the principles of the Helsinki
declaration and all individuals gave written informed consent to
participate.
Isolation of Tumor-infiltrating Immune Cells and PBMCs
and FACS Analysis
Peripheral blood mononuclear cells (PBMC) were obtained by
density gradient centrifugation using Ficoll-Hypaque (Pharmacia
Biotech, Uppsala, Sweden). Tissue specimens were obtained from
74 different patients undergoing standard-of-care surgical proce-
dures for cutaneous melanoma, at the time of primary surgery.
There were no restrictions (e.g. stage, etc) on tissues included for
this study other than confirmation of melanoma by pathology
review of H&E slides from the specimen taken for research. Tissue
was obtained fresh and immediately transported to the laboratory
in sterile saline for processing. Tissue was first minced into small
pieces followed by digestion with collagenase type IV and DNAase
(Sigma, St. Louis, MO) for 1 hr at 37uC. After digestion, the cells
extracted were washed twice in RPMI 1640 medium (Gibco,
Grand Island, NY, USA) and tumor-infiltrating mononuclear cells
were obtained by Ficoll-Hypaque density gradient centrifugation.
Both PBMC and tumor-infiltrating cells were stained for live/dead
discrimination using Invitrogen LIVE/DEAD fixable violet dead
cell stain kit (Invitrogen, Carlsbad, CA). Fc receptor blocking was
performed with human immunoglobulin (Sigma, 3 mg/ml final
concentration) followed by surface staining with different fluoro-
chrome-conjugated antibodies to study the composition of the
different subpopulations.
The fluorescein isothiocyanate (FITC)-, phycoerythrin (PE)-,
PE-Cy5- or allophycocyanin (APC)- conjugated monoclonal
antibodies (mAbs) used to characterized the entire population
were the following: anti-CD3, anti-CD4, anti-CD8, anti-CD14,
anti-CD19, anti-CD56, anti-pan cd TCR, anti-Vd1, anti-Vd2,
anti-CD27 and anti-CD45RA, all purchased from BD Biosciences
(Mountain View, CA). Expression of surface markers was de-
termined by flow cytometry on an FACSCalibur or FACSCanto II
Flow Cytometer with the use of FlowJo software (BD Biosciences).
The gating strategy involved progressively measuring total cells;
viable cells only; lymphomonocytes and specific cell types. For
every sample 100.000 nucleated cells were acquired and values are
expressed as percentage of viable lymphomonocytes, as gated by
forward and side scatter. Negative control (background) values
were not subtracted, as the median backgrounds for isotype-
matched mAbs was 0.0028% (range, 0.000%–0.0063%). Samples
were considered positive if the number of cells was equal to or
greater than 0.01% and at least 10 clustered events were apparent.
This empiric cut-off value was predicted to be .90% different
from background, at an a of 0.05 [40].
Generation of Polyclonal Vd1+ and Vd2+ T Cell Lines
Polyclonal Vd1+ and Vd2+ T cell lines were generated by first
enriching bulk tumor infiltrating cells using a cd T cell isolation kit
(Miltenyi Biotec, Bergisch Gladbach, Germany), followed by
sorting single Vd1+ and Vd2+ cd T cell through a FACSAria (BD
Biosciences) with specific mAbs. Cells (26103) were then cultured
into each well of round-bottom, 96-well plates containing 26104
irradiated (40 Gy) allogeneic PBMC, 26103 irradiated (70 Gy)
EBV-transformed B cells, 0.5 mg/ml PHA, and 200 U/ml
recombinant interleukin 2 (Proleukin; Novartis Pharma, Basel,
Switzerland). Growing lines were expanded in 200 U/ml IL-2 and
restimulated every 2 weeks. Usually, cells were collected after 4–6
weeks of culture to be used for functional assays in vitro.
Cytokine Production and Cytotoxic Assay
The cytokine production capacity of polyclonal Vd1+ and Vd2+
T cell lines was determined after stimulation with PMA (BD
Biosciences, 20 ng/ml) and ionomycin (BD Biosciences, 1 mM) for
24 h at a cell concentration of 106/ml. ELISA kits for the
detection of IFN-c and TNF-a were obtained from BD
Pharmingen and performed according to the manufacturer’s
instructions.
The human malignant melanoma A375 cell lines (a generous
gift of Dr. Ruggero De Maria, Istituto Superiore di Sanita`, Rome,
Italy), growing in adhesion in Dulbecco’s Modified Eagle’s
Medium (DME) with 10% FCS, was used as target in cocultures
with polyclonal Vd1+ and Vd2+ T cell lines obtained from 8
patients affected by melanoma. Briefly, Vd1+ and Vd2+ T cells
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resuspended at the final concentrations of 106 and 2.56106 cells/
ml were added to A375 cells (16105), to obtain the E:T ratios of
10:1 and 25:1. Cocultures were maintained for 6 hrs a 37uC in
presence of 5% of CO2. In some experiments, tumor cells were
pre-treated overnight with Zoledronate (Novartis Pharma, Basel,
Switzerland, 5 mM final concentration), before incubation with
Vd1+ or Vd2+ T cell lines. At the end of incubation, the cells were
washed with PBS and stained with 10 ml of Annexin V FITC and
10 ml of PI solution in 100 ml of 16 binding buffer (10 mM
HEPES, 140 mM NaCl, and 25 mM CaCl2) for 15 min at room
temperature in the dark, diluted in 400 ml 16binding buffer, and
immediately analysed by FACS (10,000 events/sample) to
establish the level of cells death. Samples were acquired on an
FACSCalibur and the cells were gated by forward and side scatter
on A375 melanoma target cells. The evaluation of cytotoxic
activity was based on the degree of reduction of viable target cells
(VTC) analyzed through the expression of Annexin V and
propidium iodide (Annexin V2 PI2).
Immunohistochemistry
Immunohistochemical analysis was performed on 5 mm-thick
paraffin-embedded sections of melanoma samples. Slides were
heated for antigen retrieval in 10 mM sodium citrate (pH 6.0).
After rinsing in dH2O, inhibition of endogenous peroxidase was
performed with 3% H2O2 (5 min). After two washes in TBS, slides
were incubated with 10% human serum for 20 min to clock
unspecific staining. Following elimination of excess serum, sections
were then exposed to specific antibodies against anti-human cd
TCR (purified mouse anti-human cd TCR, IgG1, BD Pharmin-
gen) or isotype-matched controls at appropriate diluitions, over-
night at 4uC. Then sections were washed in TBS and incubated
with biotinylated anti-mouse antibody for 30 min at room
temperature and treated with streptavidin-peroxidase (LSAB2
Kit, Dako). Staining was revealed using AEC substrate and
counter-stained with hematoxylin. Positive controls for cd TCR
staining consisted of normal human lymph node tissue resected for
diagnostic purposes.
Statistical Analysis
The significance of difference between groups was determined
by Student’s t test. Pearson x2, likelihood-ratio x2, Fischer’s exact
test statistics and a simple logistic regression analysis were applied
to compare the effect of cancer stage on the recovery rate and
percentage of cd T cells. Differences between subgroups with
a probability of ,0.05 were regarded as significant. All p-values
are two tailed and all statistical analyses were performed using the
STATA software package.
Results
Phenotype of Melanoma Infiltrating Immune Cells
After surgical removal of 74 primary cutaneous melanomas,
tumor-infiltrating immune cells were isolated only in 54 of them
(72.9%), and their subpopulations were studied. The greatest
numbers of infiltrating immune cells were macrophages (CD14+
cells), while CD3+ T cells were scarcely represented within the
analyzed primary melanomas (4.3%). cd T cells were the major
lymphocyte subset and accounted for approximately 50% of the
total CD3+ population (Figure 1). Of note however, cd T cells
were found only in 46 out of the 54 patients with a lymphocyte
infiltration. Frequencies of CD4+ and CD8+ T cells in tumor-
infiltrating immune cells were 37% and 13% of the CD3+
population, respectively, and percentages of B and NK lympho-
cytes were even lower than percentages of CD3+ cells (1.2% for
both CD19+ and CD56+ cells). As shown in Figure 1, there was
an extremely high variability in percentages of cells recovered
from the tested melanoma patients.
Distribution and Phenotypic Analysis of Melanoma-
infiltrating cd T Cells
To evaluate the distribution of cd T cells within melanomas, we
immunostained melanoma sections from 7 patients for pan-cd
TCR. As shown in Figure 2A–D cd+ T cells were distributed in
the periphery of the infiltrate, irrespective on whether the patients
had moderate (5 patients) or high (2 patients) amounts of tumor-
infiltrating cd T lymphocytes.
In the peripheral blood of healthy adult individuals, the
majority of cd T cells expresses the Vd2 TCR, whereas cells
carrying Vd1 dominate among intraepithelial cd T cells [23].
Vd1+ T cells were the predominant melanoma-infiltrating cd T
cell population in 23 patients (50%), while cells expressing Vd2
predominated in 19 patients (42%), and 4 patients (8%) had equal
percentages of Vd1+ and Vd2+ cells (Figure 2E). This was not due
to a bias in the overall cd T cell population in melanoma patients,
as the Vd1 to Vd2 ratio in their peripheral blood was low and
similar to that found in healthy individuals (Figure 2E).
Human cd T cells include those with naive or central-memory
phenotypes (Tnaive, CD45RA
+CD27+; TCM, CD45RA
2CD27+)
that home to secondary lymphoid organs, but that lack immediate
effector function, and those with effector-memory (TEM,
CD45RA2CD272) and terminally-differentiated (TEMRA,
CD45RA+CD272) phenotypes that home to sites of inflammation
and that display immediate effector functions as cytokine pro-
duction and cytotoxic activity [40]. We studied the memory subset
distribution of the infiltrating cd T cells, assessing the expression of
CD27 and CD45RA on Vd1+ and Vd2+ cells. The analysis
showed, that the majority of melanoma-infiltrating Vd1+ T cells
had a TEM (64.9%) and TEMRA (26.1%) phenotype, whereas Tnaive
and TCM accounted for 2.3% and 5.3%, respectively (Figure 3A).
Similarly, the melanoma infiltrating Vd2 T cells were pre-
dominantly TEM (84.5%) and TEMRA (10.4%). while Tnaive and
TCM subpopulations accounted for 1.2% and 3.7%, respectively
(Figure 3B).
Figure 1. Percentages of tumor-infiltrating immune cells in
patients with primary melanoma. Box plots of percentages of
immune cell subsets in 74 melanoma patients. Boxes represent 25th to
75th percentiles. Middle bar identifies median; whiskers show minimum
and maximum.
doi:10.1371/journal.pone.0049878.g001
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The finding that the majority of melanoma-infiltrating Vd1+ T
cells had a TEM and TEMRA phenotype is not surprising as this is
the phenotype of circulating Vd1+ T cells. However, the detection
of Vd2+ T cells with a TEM and TEMRA phenotype is intriguing as
circulating Vd2+ T cells are predominantly TCM and TEM [41].
To understand if the predominance of tumor-infiltrating Vd2+ T
cells with a TEM and TEMRA phenotype was due to the tumor
microenvironment or simply reflected an overall bias in melanoma
patients, we studied the phenotype of cd T cells in the peripheral
blood of 15 healthy subjects and 46 melanoma patients, and
compared them with the infiltrating cd T cells. As shown in
Figure 4A, Vd2+ T cells obtained from peripheral blood of
healthy subjects showed a predominant TCM phenotype (76.8%),
and similarly did circulating Vd2+ cd T cells from melanoma
patients (69.6%). Conversely, the TCM cell subset was very poorly
Figure 2. Localization and subset phenotype of melanoma-infiltrating cd T cells. (A–D) immunohistochemistry staining of melanoma
tissues using antibodies directed against the cd TCR, as revealed by AEC (red staining). Nuclei are revealed by hematoxylin staining (blue). (A) shows
lymph node staining for cd TCR, as a positive control. Different histotypes of melanoma are represented: superficial intraepithelial melanoma (B),
superficial spreading melanoma (C) and ulcerated nodular melanoma infiltrating the dermis (D). Melanomas with moderate amounts of cd+ tumor-
infiltrating lymphocytes (B and C) and high (D) levels of cd+ T cells are shown. In all cases, cd+ T cells are distributed in the periphery of the infiltrate.
(E) Percentages of total cd T cells, and their Vd1 and Vd2 subsets in TILs and PBMCs of patients with melanoma.
doi:10.1371/journal.pone.0049878.g002
Figure 3. Memory and effector phenotypes of Vd1 and Vd2 T cells in TILs of patients with melanoma. TILs from patients with melanoma
were obtained as described under Materials and Methods and were stained with anti-Vd1, anti-Vd2, anti-CD45RA and CD27 mAbs. Percentages of
Tnaive (CD45RA
+CD27+), TCM (CD45RA
2CD27+), TEM (CD45RA
2CD272) and TEMRA (CD45RA
+CD272) cells were determined by FACS analysis. Shown are
cumulative data for Vd1 and Vd2 T cells.
doi:10.1371/journal.pone.0049878.g003
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represented in the infiltrating cd T cell population (approximately
3.7%).
An opposite pattern was found for Vd2+ cd T cells with a TEM
phenotype, which were poorly represented amongst circulating
Vd2+ cd T cells of healthy subjects (13%) and melanoma patients
(21%), while being the predominant population (84.5%) in the
melanoma-infiltrating cd T cells.
These results clearly demonstrate that the cells committed to
effector activities at the tumor site are phenotypically different
respect to circulating Vd2+ cd T cells. Figure 4B shows a typical
FACS analysis of one representative sample, indicating the
different phenotype of Vd2+ cd T cells in each analyzed group.
Cytokine Production and Cytotoxic Activity of
Melanoma-infiltrating cd T Cells
The yield of primary cd T cells isolated from melanomas did
not allow a detailed investigation; therefore, functional studies
were performed with a panel of Vd1+ and Vd2+ polyclonal cd T
cell lines (see also Materials and Methods) derived from tumor-
infiltrating immune cells of 8 melanoma patients. All tested Vd1+
and Vd2+ T cell lines produced very high levels of the
proinflammatory cytokines TNF-a and IFN-c after stimulation
with PMA and ionomycin (Figure 5A and B). To address the
potential role of cutaneous cd T cells in tumor surveillance, their
ability to mount cytolytic responses against melanoma cells was
examined. Tumor-derived, polyclonal Vd1+ and Vd2+ T cell lines
were tested in cytotoxicity assays using heterologous melanoma
cell lines as targets. Of the eight tested Vd1+ T cell lines, five
exerted robust cytotoxic responses against the melanoma cell line
A375, resulting in up to 70% target cell death at an E:T cell ratio
of 25:1; one line had poor, yet detectable cytotoxic activity,
whereas two lines failed to kill (Figure 5C).
The cytotoxic capacity of melanoma-derived, polyclonal Vd2+
T cell lines was examined in similar experimental conditions.
Remarkably, and in clear contrast to Vd1+ T cell lines, only two
out of eight tested Vd2+ T cell lines demonstrated clear cytotoxic
activity against A375 melanoma cells, with an average of 75%
target cell lysis at an E:T cell ratio of 25:1 (Figure 5D); two cell
lines had low cytotoxic activity, while four lines completely failed
to kill. However, pre-treatment of the A375 melanoma target cells
with zoledronate, a drug shown to sensitize several tumor targets
to the cytolytic activity of Vd2+ T cells, was able to increase their
killing by Vd2+ T cell lines in four instances (Figure 5C).
Clinical Correlates and Statistical Considerations
cd T cells were found in 46 of the 74 patients (62.0%). The
success rate of cd T cells isolation ranged from over 60% in
patients at stage 0 or I, to 86% in patients at stage II, 42% in
patients at stage III and 0% for patients in stage IV. When data
were cumulated for patients with localized melanoma or
disseminated disease (e.g., absence or presence of metastases), cd
T cells were recovered in 71.9% of non-metastastic patients (stage
0-I-II), and in 29.4% of patients with metastases (stage III and IV)
(Table 1). We analyzed the statistical significance of the
association between cd cells isolation rate in tumor-infiltrating
immune cells and the stage of disease. The standard non-
parametric approach exploited when outcomes are binary relies
on the Kendall’s Tau-b. In our sample this association is equal to
20.367 with an asymptotic standard error (ASE) of 0.112,
indicating that cd T cells and the cancer’s stage are negatively
correlated. However to check whether this association is statisti-
cally significant or rather it is simply due to sampling variations,
we tested the null hypothesis of no association using the Pearson x2
test. This is asymptotically distributed as x2 distribution with 1 df.
In our study, the Pearson x2 is equal to 10.06 with a p-value of
0.002. Thus the null hypothesis is rejected at 1% statistical
significant level. For robustness of statistical significance, we have
also computed the LR x2 statistic and the Fischer’s exact test.
Generally these tests perform better than the Pearson x2 test when
cell frequencies are small. Also in this case the LR x2 test (p-value
of 0.002) and the Fisher’s exact test (p-value 0.003) rejects the null
of no association even at 1% significance level. Finally we have
also run a simple logit model to estimate the odds-ratio between
Figure 4. Comparison of Vd2 T cell subset distribution in TILS and PBMCs form patients with melanoma and healthy individuals.
TILs from patients with melanoma (TIL-Mel) and PBMCs from patients with melanoma (PBMC-Mel) and healthy subjects (PBMC-HS) were obtained as
described under Materials and Methods and were stained with anti-Vd2, anti-CD45RA and CD27 mAbs. Percentages of Tnaive (CD45RA
+CD27+), TCM
(CD45RA2CD27+), TEM (CD45RA
2CD272) and TEMRA (CD45RA
+CD272) cells were determined by FACS analysis. (A) Shows cumulative data for Vd2 T
cells and (B) shows representative flow cytometry panels from a healthy subject and a patient with melanoma, upon gating on Vd2+ cells and staining
with CD27 and CD45RA. *p,0.001 and **p,0.01 when compared to values in PBMCs.
doi:10.1371/journal.pone.0049878.g004
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cancer’s stage and cd T cell isolation rate. The odds ratio is 0.16
(SE = 0.10).
The prima facie inverse correlation between melanoma stage and
the recovery rate of cd T cells was provocative, and was
investigated further. As shown in Table 1, percentages of total
cd T cells and their Vd1 subset, among infiltrating lymphomo-
nocytes, were lower in patients at stages III and IV, even if values
at stage III were not significantly different from values at stages 0, I
and II. Also percentages of Vd2 cells were lower in patients at
stage III and IV, but values at stage III attained statistical
Figure 5. Cytokine production capacity and cytotoxic activity of melanoma-derived cd T cell lines. Cytokine production by melanoma-
derived Vd1 (A) and Vd2 (B) cell lines was assessed by ELISA analysis of supernatants after 24-hrs stimulation with PMA and ionomycin. Cytokines were
,1 ng/ml in the supernatants of unstimulated Vd1 and Vd2 T cell cultures. Values are the mean from duplicate wells. The cytotoxic activity of
melanoma derived Vd1 (C) and Vd2 (D) T cell lines was analyzed for against the autologous melanoma cell line A375 at different E:T cell ratios. In
experiments shown in (D), A375 target cells were pre-treated with zoledronate, as described under Materials and Methods. Shown are data from
a representative experiment with 8 different T cell lines, at an E:T ratio of 25:1.
doi:10.1371/journal.pone.0049878.g005
Table 1. Association between rate of cd T cells and clinical features in patients with melanoma.
Feature cd T cells isolation rate cd T cells (% 6 SE) Vd1 T cells (% 6 SE) Vd2 T cells (% 6 SE)
Stage (TNM system)
0 6/9 (66.7%) 1.7261.07 1.2160.73 0.6060.41
I 16/26 (62.5%) 1.5260.81 0.9460.61 0.6260.42
II 19/22 (86.3%) 1.6961.03 0.9760.64 0.7160.41
III 5/12 (41.7%) 0.9760.82 0.8960.71 0.2260.23*
IV 0/5 (0%) 060 060 060
0-I-II 41/57 (71.9%) 1.6260.93 0.9860.65 0.6760.42
III-IV 5/17 (29.4%) 0.6760.72 0.6360.61 0.1760.17**
Total 46/74 (62.1%)
The rate of cd T cell isolation was calculated by dividing the number of patients from with cd T cells were isolated by the total number of patients.
*p = 0.038 when compared to values at stage 0, p = 0.026 when compared to values at stage I and p= 0.013 when compared to values at stage II.
**p = 0.00026 when compared to values at stages 0-I-II.
doi:10.1371/journal.pone.0049878.t001
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significance as compared to patients at stage 0, I and II. When
data were cumulated for patients with localized melanoma or
disseminated disease (e.g., absence or presence of metastases),
there was a clear trend whereby percentages of total cd T cells and
their Vd1 and Vd2 subsets declined in patients with advanced
disease, but again only differences in percentages of Vd2 T cells
were significantly different. These results indicate that percentages
of tumor-infiltrating Vd2 T cells are inversely correlated with the
stage of disease in patients with melanoma.
Discussion
Substantial evidence indicates that the immune system partici-
pates in cancer pathogenesis and may contribute to either disease
progression or inhibition of tumor growth. It is common for
regressing tumor lesions to be markedly infiltrated by mono-
nuclear cells and the presence of T cells has been associated with
improved prognosis in patients with different types of carcinomas
[8–10]. Relevant to this study, patients with lymphocytic infiltrate
in primary melanomas had lower risk of metastasis and death than
patients with sparse or absent infiltrate [4,5].
cd T lymphocytes are important effector cells of the immune
system that play a role in the anti-tumor surveillance in the
periphery. For instance, murine skin harbors a major population
of cd T cells, known as dendritic epidermal T cells (DETCs),
which appear to play a critical role in tumor surveillance, as
evidenced in cd T cell-deficient mice [22]. However, a counterpart
of DETCs does not exist in human epidermis, and it is thus
unclear what types of lymphocyte, if any, mediate equivalent
immune surveillance functions in human skin.
Results herewith reported show that cd T cells are the major
lymphocyte population infiltrating melanoma, and both Vd1+ and
Vd2+ cells are involved. This finding is not surprising as it
recapitulates the microenvironmental conditions occurring under
physiologic conditions in vivo in humans. In fact, Vd1+ T cells are
the prevalent cd T cell population in human tissues including
intestinal epithelium and skin [42]. However, our study also
demonstrate the presence of Vd2+ T cells among melanoma-
infiltrating immune cells, which are the major cd T cell population
in approximately 40% of patients. Given that Vd2+ T cells are
absent from normal skin [42], their presence in the context of
melanoma is highly suggestive of a migratory process from the
blood or lymphoid tissues. Accordingly, more than 90% of
melanoma-infiltrating Vd2+ T cells have a TEM and TEMRA
phenotype, indicative of cells that home to sites of inflammation
and that display immediate effector functions as cytokine pro-
duction or cytotoxic activity [41]. Very recently, a distinct subset
of proinflammatory CLA+, CCR6+ Vc9Vd2 T cells has been
described which is rapidly recruited from the blood to the skin
compartment [43], but we do not have evidence if the Vc9Vd2 T
cells which infiltrate melanoma belong to this novel cd T cell
subset.
Conversely, circulating Vd2+ T cells from the same patient have
a predominant TCM phenotype, similarly to that occurring in
healthy subjects, and that identifies cells that home to secondary
lymphoid organs, but that lack immediate effector function.
Collectively, these results strongly indicate that while Vd1+ T
cells may be activated locally in the tumor microenvironment,
Vd2+ T cells are most likely recruited from the peripheral blood or
secondary lymphoid organs by virtue of a migratory process
orchestrated by chemokines or other inflammatory molecules
produced at the tumor site. Both the resident Vd1+ and the
migrated Vd2+ T cells may contribute to control tumor growth, as
suggested by their ability to produce cytokines with proven anti-
tumor activity (TNF-a and IFN-c) and to kill melanoma cell
targets in vitro. However, substantial differences were found in the
cytotoxic capability of Vd1+ and Vd2+ T cells: while the majority
of Vd1+ T cell lines exerted cytotoxic activity against the
melanoma cell line A375, only two out of eight tested Vd2+ T
cell lines were able to kill this tumor target cell. Moreover,
treatment with zoledronate was able to sensitize melanoma cell
targets to Vc9Vd2 T cell cytotoxicity.
It has been demonstrated that treatment of tumor cells with
zoledronate leads to the intracellular accumulation of phosphoan-
tigens (typically IPP), thus favoring recognition and killing of
tumor cells by the reactive Vc9Vd2 T lymphocytes [44,45]. How
far other molecules, such as the ectopically expressed F1-ATPase,
which has been claimed to serve as the Vc9Vd2 TCR ligand
expressed by tumor cells [46], are involved in IPP recognition
remains unclear.
In our study, the presence of cd cells in tumor-infiltrating
immune cells correlates with early stage melanomas as indicated
by higher rate of cd T cells isolation and higher percentages of cd
T cells in patients at early stage of development of melanoma
(stage 0-I-II) and without metastasis. Of note, cd cells were
scarcely found or absent in patients at an advanced stage (stage III
and IV) and in metastatic melanomas (71.9% non metastatic vs
29.4% metastatic) and this was particularly evident for Vd2 T cells
which showed an inverse correlation with the stage of melanoma,
a finding which could be associated with a poor effectiveness of the
local immune response at advanced phases of tumor progression.
Recent studies have shown a high frequency of cd T cells among
TILs from patients with different types of cancer, but the clinical
relevance of these intratumoral cd T cells is unknown. In contrast
to the present study, percentages of cd T cells within renal cell
carcinoma fail to correlate with any prognostic features [47] and
intratumoral cd T cell numbers are positively correlated with
advanced tumor stages, HER2 expression status, and high lymph
node metastasis but inversely correlated with relapse-free survival
and overall survival of breast cancer patients [48]. Actually we can
only speculate on the discrepancy between melanoma and renal
and breast cancer. cd cells comprise two major subsets (Vd1 and
Vd2) with different memory/effector phenotypes and heteroge-
neous functional properties that can be discerned by the use of
additional markers (cytokine production, cytotoxic activity,
migratory properties); hence positive or negative correlation with
prognosis may depend on the specific cd subset recruited at the
tumor site. Furthermore, the net biologic effects of cd T cells may
depend on the tumor type and the tumor site, perhaps reflecting
microenvironmental differences.
The analysis of TIL responses to cancer antigens has served to
define many of the relevant TAs, and adoptive cellular immuno-
therapy with TILs has achieved some of the most remarkable
immunotherapy results to date [13,49]. For instance, high clinical
response rates have been obtained in metastatic melanoma
patients with TIL-based protocols in combination with non-
myeloablative lymphodepleting chemotherapy (cyclophosphamide
and fludarabine) immediately prior or added to infusion of TIL
and high-dose IL-2 therapy [11,13].
Our study, showing that cd T cells are found in the majority of
melanoma-infiltrating lymphocyte populations, and they recognize
and kill melanoma cells, suggest that a natural immune response
mediated by these lymphocytes may contribute to the immuno-
surveillance of melanoma. Such observations may foster the
development of novel alternative or adjuvant therapies targeting
cd T cells for the treatment of melanoma patients. This might be
achieved for instance by stimulating cd T cells in these patients
through injection of zoledronate and IL-2, as recently performed
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by our group in prostate and breast cancer [50,51]. Alternatively,
it could be achieved by adoptive transfer of ex vivo expanded
autologous cd T cells derived from cancer patients [52,53]. Both
the cd T cell transfer and the infusion of bisphosphonates have
been proven to be well tolerated [50,53].
In conclusion, it can be speculated that the in vitro expansion of
cd T cells and the subsequent infusion of these cells plus
zoledronate, in combination with other antitumor agents may be
of significant clinical benefit in the treatment of melanoma; in
turn, this could allow us to extend the life span of patients and
thereby to increase the window of the patients’ availability for
other more specific molecular approaches.
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